banner

Posts tagged as: learn technical analysis back to homepage

Aeterna Zentaris Stock Chart Analysis Video Aeterna Zentaris Stock Chart Analysis Video(0)

Three straight days of closing ahead has the AEterna Zentaris chart on watch for continued upward pressure. Shares rose 8.5 percent on Tuesday to close near the high of the day on increased volume, which is a bullish sign as the stock nears resistance. Shares traded as low as $1.75 last week, but have recovered to close on Tuesday at $2.16 on Read More

Nautilus Stock Chart Analysis Video Nautilus Stock Chart Analysis Video(0)

Although the chart for Nautilus Inc. (NYSE: NLS) fell sharply in July, the stock has still posted solid gains for 2012 and is back on the rise. Resistance is ahead around $3.00, but the chart is showing bullish signs of trend and momentum, indicating that if the resistance is broken, a run at the 52-week high could happen.

Headquartered in Vancouver, Washington, Nautilus, Inc. is a global fitness products company providing innovative, quality solutions to help people achieve a healthy lifestyle. With a brand portfolio including Nautilus®, Bowflex®, TreadClimber®, Schwinn®, Schwinn FitnessTM, Universal® and CoreBody Reformer™, Nautilus markets innovative fitness products through Direct and Retail channels.


Nautilus Group (NLS) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

PositiveID Stock Chart Analysis Video PositiveID Stock Chart Analysis Video(0)

The PositiveID (OTCBB: PSID) stock chart made a new 52-week low yesterday before buying pressure pulled the stock price up to close the day with a hammer/doji candle. A possible reversal candle, the chart is holding support firmly at 3 cents with resistance not coming into play until 4 cents. A long-term positive divergence between the MACD and the PPS has the chart on radar for an overall trend shift. Read More

Anthera Pharmaceuticals Stock Chart Analysis Video Anthera Pharmaceuticals Stock Chart Analysis Video(0)

A look at Anthera Pharmaceuticals’ (NASDAQ: ANTH) 15-minute charts, combined with the daily charts, shows that the stock could be aligning for a “dead cat bounce.” Technical traders will be looking for a new support level to be established and any upward movement to meet resistance near $0.80, where the stock still has a short-term, open gap that is unfilled presently.

The stock has languished Read More

Takedown Entertainment Stock Chart Analysis Video Takedown Entertainment Stock Chart Analysis Video(0)

The stock chart for Takedown Entertainment, Inc. (OTCBB: TKDN) is holding a base at 2 cents and pushed through a resistance point at $0.022 with a slight increase in volume on Tuesday. The indicators have been trending towards bullish positions over the last month; giving hints of a potential rise in price and reversal of the downward trend. The candles Read More

Mustang Alliances Stock Chart Analysis Video(0)

Mustang Alliances (OTCBB:MSTG) has been in a strong uptrend for several months. After a consolidation, the price per share has held the 50dma and is back on the climb looking to challenge the old highs at $1.48. Read More

Ecoland International Stock Chart Analysis Video(0)

After a monster move from 10 cents to $1.35, ECIT has had a large retracement back to initial breakout points. Although the PPS has slipped just below the original resistance point, it is holding between the 50 and 200 dma’s and on watch to take-on some bullish pressure again. Read More

BioLargo Stock Chart Analysis Video(0)

A thin-floater, the BioLargo chart is climbing again as it has historically done off a bottom support at 20 cents. Technical traders will be watching for a 20 percent climb to take out resistance at 40 cents, which could free a path to the next resistance at 60 cents. Read More

Sino Payments Video Stock Chart - Revisted for New Climb(0)

We are re-visiting the Sino Payments, Inc. (OTCQB:SNPY) after a sharp make a new 52-week high, the SNPY chart has consolidated and is starting to climb again. Charts must retrace to reset indicators and SNPY has done that and now looks positioned to challenge the highs again. Volume is increasing Read More

Medisafe1 Technologies Stock Chart Analysis Video Medisafe1 Technologies Stock Chart Analysis Video(0)

The Medisafe1 Technologies (OTCBB:MFTH) stock chart is consolidating after a large ten-bagger type of move. The consolidation pattern is tightening which will have traders watching for the breakout of resistance at 1.5 cents with a potential upside to resistance at Read More



Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.